Xu LY, Yu Y, Cen LS. Insight into the efficacy and safety of pirfenidone: The treatment of idiopathic pulmonary fibrosis. World J Clin Cases 2025; 13(14): 98769 [DOI: 10.12998/wjcc.v13.i14.98769]
Corresponding Author of This Article
Lu-Sha Cen, PhD, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2025; 13(14): 98769 Published online May 16, 2025. doi: 10.12998/wjcc.v13.i14.98769
Insight into the efficacy and safety of pirfenidone: The treatment of idiopathic pulmonary fibrosis
Li-Ying Xu, Yi Yu, Lu-Sha Cen
Li-Ying Xu, Department of Medical Administration, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Yi Yu, The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou 310051, Zhejiang Province, China
Lu-Sha Cen, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, Zhejiang Province, China
Co-first authors: Li-Ying Xu and Yi Yu.
Author contributions: Xu LY wrote the manuscript; Yu Y prepared materials and unified the style; Cen LS provided the resources and funds; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lu-Sha Cen, PhD, Department of Ophthalmology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 54 Youdian Road, Hangzhou 310006, Zhejiang Province, China. cenlusa2@sina.com
Received: July 5, 2024 Revised: December 9, 2024 Accepted: January 2, 2025 Published online: May 16, 2025 Processing time: 194 Days and 4.7 Hours
Abstract
Idiopathic pulmonary fibrosis (IPF) has a poor prognosis if left untreated; therefore, early treatment with pirfenidone is crucial. Lei et al conducted a retrospective analysis to evaluate the effectiveness of early pirfenidone treatment on lung function in 113 patients with IPF. In addition to other research, pirfenidone has demonstrated efficacy in patients at all stages of IPF once correct diagnosis has been made. In advanced IPF, we include the requirement for pirfenidone. Therefore, it is essential to choose an appropriate method of administration method, such as inhalation. This may circumvent the drawbacks of the high cost and possible adverse effects of this drug.
Core Tip: Early intervention is essential for idiopathic pulmonary fibrosis (IPF). Lei et al have shown that timely initiation of pirfenidone treatment in individuals diagnosed with IPF can effectively reduce the occurrence of adverse reactions. Moreover, choosing an appropriate pharmaceutical approach or timing for IPF treatment could be beneficial; however, further evidence is required.
